UPDATE: UBS Starts Obalon Therapeutics (OBLN) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- Comstock Resources signs $1.65B deal with SOCAR, $450M JV
UPDATE: Stifel Starts Obalon Therapeutics (OBLN) at Buy
October 31, 2016 7:54 AM EDT(Updated - October 31, 2016 8:42 AM EDT)
Stifel initiated coverage on Obalon Therapeutics (NASDAQ: OBLN) with a Buy rating and a price target of $18.
Analyst Rick Wise said, "This target ascribes a 4.5x EV/R multiple applied to our 2020E, $96M revenue projection, discounted 18%... More
Canaccord Genuity Starts Obalon Therapeutics (OBLN) at Buy
October 31, 2016 7:54 AM EDTCanaccord Genuity initiated coverage on Obalon Therapeutics (NASDAQ: OBLN) with a Buy rating and a price target of $17.00.
For an analyst ratings summary and ratings history on Obalon Therapeutics click here. For more ratings news on Obalon Therapeutics click here.
Shares of Obalon Therapeutics closed at $13.80 yesterday.
... MoreBTIG Starts Obalon Therapeutics (OBLN) at Buy
October 31, 2016 7:53 AM EDTBTIG initiated coverage on Obalon Therapeutics (NASDAQ: OBLN) with a Buy rating and a price target of $20.
Analyst Sean Lavin said, "The obesity market is huge and growing. Technologies, surgeries, and pharmaceuticals prior to intragastric balloons have either been ineffective, unsafe, too... More
